|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ӳ��ή����̦ |
|
���� |
|
����֢ |
|
���� |
| ��������������� | |
|
������ |
|
�˺� |
| PubMed | |
|
Article by ZHANG Qing-song |
|
Article by GU Heng |
Ӳ��ή����̦���о���չ
������, �˺�
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ� 210042
Ӳ��ή����̦��һ�ֺ÷�������ֳ����λ��������֢�Լ���,ǣ�浽�ٴ���ͬѧ��.������о���ʾӲ����ή����̦������һ���뿹ϸ������ʵ���-1��ص����������Լ���.�ٴ�����Ϊ��ֳ����λή����ɫ�߿�,���䱻��Ϊ�������۰��й�,���б�Ҫ�������.Ӳ��ή����̦�����Ƴ���Ҫ��ѧ�Ƶ�Э����ʹ����ø��õ��ٴ���Ч.
Advances in the Research of Lichen Sderosus et Atrophicus
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Lichen sclerosus et atrophicus(LS&A) is a chronic inflammatory disease predominantly occurring in external genital area.Recently,studies indicate that LS&A may be an autoimmune disease associated with extracellular matrix protein-1.The classic clinical picture is of atrophic white plaques in genital region.Due to the potential to progress into genital squamous cell carcinoma,long-term monitoring is required.A multidisciplinary approach has to be carried out for better therapeutic effect on LS&A.
[2] Gross T,Wagner A,Ugurel S,et al.Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus.Dermatology,2001,202:198-202.
[3] Sander CS,Ali I,Dean D,et al.Oxidative stress is implicated in the pathogenesis of lichen sclerosus.Br J Dermatol,2004,151:627.
[4] Oyama N,Chan I,Neill SM,et al.Autoantibodies to extracellular matrix protein 1 in lichen sclerosus.Lancet,2003,362:118-123.
[5] Foldes-Papp Z,Reich O,Demel U,et al.Lack of specific immunological disease pattern in vulvar lichen sclerosus.Exp Mol Pathol,2005,79:176-185.
[6] Marren P,Yell J,Chamock FM,et al.The association between lichen sclerosus and antigens of the HLA system.Br J Dermatol,1995,132:197-203.
[7] Gao XH,Barnardo MC,Winsey S,et al.The association between HLA DR,DQ antigens,and vulval lichen sclerosus in the UK:HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus,and HLA DRB10301/04 and its associated DRB 10301/04/DQB10201/02/03 haplotype protects from vulval lichen sclerosus.J Invest Dermatol,2005,125:895-899.
[8] Senturk N,Aydin F,Birinci A,et al.Coexistence of HLA-B*08 and HLA-B*18 in four siblings with Lichen sclerosus.Dermatology,2004,208:64-66.
[9] Clay FE,Cork MJ,Tarlow JK,et al.Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus.Hum Genet,1994,94:407-410.
[10] Dillon WI,Saed GM,Fivenson DP.Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea,scleroderma,or lichen sclerosus et atrophicus of patients from North America.J Am Acad Dermatol,1995,33:617-620.
[11] Sideri M,Origoni M,Spinaci L,et al.Topical testosterone in the treatment of vulvar lichen sclerosus.Int J Gynaecol Obstet,1994,46:53-56.
[12] Criado PR,Lima FH,Miguel DS,et al.Lichen sclerosus-a keratotic variant.J Eur Acad Dermatol Venereol,2002,16:504-505.
[13] Kaur S,Thami GP,Kanwar AJ,et al.Linear oro-facial lichen sclerosus.Clin Exp Dermatol,2002,27:467-470.
[14] Citarella L,Massone C,Kerl H,et al.Lichen sclerosus with histopathologic features simulating early mycosis fungoides.Am J Dermatopathol,2003,25:463-465.
[15] Chen HC,Kadono T,Mimura Y,et al.High-frequency ultrasound as a useful device in the preliminary differentiation of lichen sclerosus et atrophicus from morphea.J Dermatol,2004,31:556-559.
[16] Jones RW,Sadler L,Grant S,et al.Clinically identifying women with vulvar lichen sclerosus at increased risk of squamous cell carcinoma:a case-control study.J Reprod Med,2004,49:808-811.
[17] Powell J,Robson A,Cranston D,et al.High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis.Br J Dermatol,2001,145:85-89.
[18] Rolfe K J,Crow JC,Reid WM,et al.The effect of topical corticosteroids on Ki67 and p53 expression in vulval lichen sclerosus.Br J Dermatol,2002,147:503-508.
[19] Cooper SM,Gao XH,Powell JJ,et al.Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol,2004,140:702-706.
[20] Renaud-Vilmer C,Cavelier-Balloy B,Porcher R,et al.Vulvar lichen sclerosus:effect of long-term topical application of a potent steroid on the course of the disease.Arch Dermatol,2004,140:709-712.
[21] Bohm M,Frieling U,Luger TA,et al.Successful treatment of anogenital lichen sclerosus with topical tacrolimus.Arch Dermatol,2003,139:922-924.
[22] Basak PY,Basak K.Lichen sclerosus et atrophicus of the scalp:satisfactory response to acitretin.J Eur Acad Dermatol Venereol,2002,16:183-185.
[23] Hillemanns P,Untch M,Prove F,et al.Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid.Obstet Gynecol,1999,93:71-74.
[24] ���־,���DZ�,����ֱ,��.�۽���������������ɫ������о�.�л���������־,2004,39:373-377.
[25] Dawe RS.Ultraviolet A1 phototherapy.Br J Dermatol,2003,148:626-637.